Pharma BD Deal Intelligence
Data-quality flag: this was AstraZeneca DIVESTING its anaesthetics portfolio TO Aspen Global — not AZ acquiring Aspen — but the underlying transaction aged as a clean win-win: AZ monetized non-core assets to fund oncology, and the portfolio became a durable, material cash-generating segment for Aspen.
Full analysis, sources & comparables →AstraZeneca's $770M ex-US anaesthetics handoff fits a 2016 asset-shedding pattern aligned with CEO Pascal Soriot's strategic focus on three core therapy areas…
Aspen's $770M acquisition of AZ's seven-product anaesthetics portfolio extends the South African specialty player's emerging-market commercial reach into…
The 2017 follow-on transaction (US rights) reinforced strategic intent — AZ ultimately divested all remaining anaesthetics rights to Aspen, completing the…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
AstraZeneca sold ex-U.S. commercialization rights for its seven-product anaesthetics portfolio to Aspen Global for $520M upfront plus up to $250M in product sales-related milestones, plus double-digit trademark royalties. Portfolio comprised Diprivan (general anaesthesia), EMLA (topical), and five local anaesthetics. Completed September 2016. Part of AstraZeneca's strategy to divest non-core mature assets.
Data-quality flag: this was AstraZeneca DIVESTING its anaesthetics portfolio TO Aspen Global — not AZ acquiring Aspen — but the underlying transaction aged as a clean win-win: AZ monetized non-core assets to fund oncology, and the portfolio became a durable, material cash-generating segment for Aspen.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Aspen Global Inc. (Aspen Pharmacare) (this deal) | 2016 | $770M | 69 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2016 deals · AstraZeneca PLC deals · Other deals